Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316017 · ClinicalTrials.gov registry record · Phase 3
Hypertonic Resuscitation Following Traumatic Injury
A Phase 3 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 3
- Development phase
- 895
- Enrollment target
NCT00316017 is a Phase 3 study that was terminated before completion, run by University of Washington. The registered enrollment target is 895 participants.
The verdict
NCT00316017, a Phase 3 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 895 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock. Injury and lost blood from trauma can cause your body to be in shock (low blood pressure related to blood loss). This decreased blood flow can lead to organ damage. In order to restore the blood pressure and blood flow, the medics give fluids into the patients' veins as soon as possible. This is called "resuscitation." The resuscitation fluid most commonly used is "isotonic" or one that is the same concentration as the blood. The investigators are trying to determine if infusing a "hypertonic" fluid (or one more concentrated than the blood) can increase the blood pressure and restore blood flow more efficiently. The hypertonic fluids the investigators are using are called hypertonic saline with dextran (HSD) and hypertonic saline (no dextran). Hypertonic saline is a salt solution that is slightly more concentrated than your blood. Dextran is a sugar solution.
Interventions
- DRUG 0.9% normal saline
- DRUG 7.5% hypertonic saline/6% Dextran-70 (HSD)
- DRUG 7.5% hypertonic saline (HS)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 895 participants |
| Start Date | 2006-05 |
| Est. Completion | 2009-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316017
The ClinicalTrials.gov registry entry for NCT00316017 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 895 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which 0.9% normal saline is the first listed.
NCT00316017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316017 about?
NCT00316017 is a clinical study titled "Hypertonic Resuscitation Following Traumatic Injury". The purpose of this study is to determine if hypertonic saline with and without dextran can improve overall survival in victims of trauma with shock. Injury and lost blood from trauma can cause your body to be in shock (low blood pressure related to blood loss). This decreased blood flow can lead t...
What is the current status of trial NCT00316017?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 895 participants. The study started on 2006-05. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00316017?
The interventions under investigation include: 0.9% normal saline (DRUG), 7.5% hypertonic saline/6% Dextran-70 (HSD) (DRUG), 7.5% hypertonic saline (HS) (DRUG).
Who is sponsoring clinical trial NCT00316017?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.